A Phase I Randomized Placebo Controlled Trial of the Safety of 3% SPL7013 Gel (VivaGel®) in Healthy Young Women Administered Twice Daily for 14 Days

• Craig R. Cohen ,

  * E-mail: ccohen@globalhealth.ucsf.edu

  Affiliation Department of Obstetrics, Gynecology and Reproductive Science, University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Joelle Brown,

  Affiliation Department of Epidemiology, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• Anna-Barbara Moscicki,

  Affiliation Department of Pediatrics, University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Elizabeth A. Bukusi,

  Affiliation Center for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya

  ⨯
• Jeremy R. A. Paull,

  Affiliation Starpharma Pty Ltd, Melbourne, Australia

  ⨯
• Clare F. Price,

  Affiliation Starpharma Pty Ltd, Melbourne, Australia

  ⨯
• Stephen Shiboski

  Affiliation Department of Biostatistics, University of California San Francisco, San Francisco, California, United States of America

  ⨯